Malignant News and Research

RSS

New cellular switch could eventually inhibit growth of aggressive malignant brain tumor

Researchers at UT Southwestern Medical Center have identified a cellular switch that potentially can be turned off and on to slow down, and eventually inhibit the growth of the most commonly diagnosed and aggressive malignant brain tumor.

21 Sep 2013

Researchers discover new mechanism involving p53 to fight against aggressive cancers

Researchers at A*STAR's Singapore Immunology Network (SIgN) have discovered a new mechanism involving p53, the famous tumour suppressor, to fight against aggressive cancers.

20 Sep 2013

Cardiovascular mortality in schizophrenia may be underestimated

Cardiovascular causes account for about a quarter of deaths of patients with schizophrenia and may also contribute to the high rate of unexplained deaths, say researchers.

17 Sep 2013

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.

16 Sep 2013

Three-gene biomarker can help determine treatment option for early prostate cancer

The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center.

13 Sep 2013

T-rays are ideal for detecting early signs of melanoma

The technology that peeks underneath clothing at airport security screening check points has great potential for looking underneath human skin to diagnose cancer at its earliest and most treatable stages, a scientist said here today.

12 Sep 2013

GGO-dominant lung tumors have excellent prognosis

Ground glass opacity-dominant clinical stage IA lung adenocarcinoma is a low-grade malignancy with an “excellent” prognosis, Japanese researchers believe.

10 Sep 2013

Severity of sleep apnoea can independently predict aggressiveness of skin melanoma

The severity of sleep apnoea can independently predict the aggressiveness of malignant skin melanoma, according to a new study.

10 Sep 2013

Researchers investigate importance of STAT1 phosphorylation in NK cells

Since its discovery in the early 1990s, the protein STAT1 (Signal Transducer and Activator of Transcription 1) has been found to be central in passing signals across immune cells, ensuring that our bodies react quickly and appropriately to threats from viruses or other pathogens.

7 Sep 2013

BMP linked to increased risk of benign tumors, not cancers

Patients undergoing spinal fusion surgery with bone morphogenetic protein (BMP) appear to be at increased risk of benign tumors—but not cancers, reports a study in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

7 Sep 2013

ESMO recognises oncologists with prestigious awards

The European Society for Medical Oncology, the leading pan-European organisation representing medical oncology professionals, announced today the recipients of the annual society's prestigious awards, recognising excellence in oncology.

5 Sep 2013

Ontario researchers develop evidence-based recommendations for lung cancer screening

Lung cancer is the most common cause of cancer death in Ontario. Screening for lung cancer using low-dose computed tomography has been the subject of many research studies since the 1990s. The National Lung Screening Trial compared LDCT with chest radiograph in high-risk populations and found a 20 percent reduction in lung cancer mortality at 6 years with LDCT after an initial scan and two annual rounds of screening.

5 Sep 2013

Researchers discover new way to target senescent cancer cells for destruction

Resting cancer cells can be selectively destroyed by inhibiting their energy metabolism. This is the recent discovery by researchers at Charité Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine (MDC) in Berlin-Buch, together with other cooperation partners from Germany. The findings of their study have been published in the scientific journal Nature.

4 Sep 2013

Blind mole-rats live underground in low-oxygen environments, are long-lived and resistant to cancer

Like naked mole-rats (Heterocephalus gaber), blind mole-rats (of the genus Spalax) live underground in low-oxygen environments, are long-lived and resistant to cancer. A new study demonstrates just how cancer-resistant Spalax are, and suggests that the adaptations that help these rodents survive in low-oxygen environments also play a role in their longevity and cancer resistance.

4 Sep 2013

Researchers create specific tests to detect cancer biomarkers in patients with dermatomyositis

Researchers from major universities in the U.S. have developed specific tests to identify cancer biomarkers in patients with dermatomyositis-a systemic inflammatory disease associated with increased risk of malignancy.

3 Sep 2013

Anti-diabetic drug alogliptin meets primary endpoint in EXAMINE trial

Patients with type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial presented at the European Society of Cardiology Congress.

2 Sep 2013

Research findings could lead to new therapeutic approaches for liver cancer

Liver cancer (Hepatocellular Carcinoma, HCC) usually arises as the result of a chronic, inflammatory liver disease. The most common causes here are excessive alcohol consumption as well as a high-fat diet and also chronic infection with the hepatitis viruses B and C. In the course of the inflammatory process, the liver cells (hepatocytes) die more frequently due to programmed cell death.

30 Aug 2013

Researchers receive $3M R01 award to test new approach to treating brain tumors

With a five-year, $3 million R01 award from the National Institutes of Health, through the National Cancer Institute, a team of researchers led by Gregory Fischer, PhD, assistant professor of mechanical engineering and robotics engineering at Worcester Polytechnic Institute and director of WPI's Automation and Interventional Medicine Laboratory, will test a new, minimally invasive approach to treating brain tumors that promises to accurately destroy malignant tissue while leaving surrounding tissue unaffected.

30 Aug 2013

Researchers find new form of imaging technology to diagnose different types of cancer

Researchers from University Hospitals Case Medical Center have published findings that a new form of imaging -- PET/MRI -- is promising for several types of cancer.

30 Aug 2013

Malignant Hyperthermia Scientific Conference to be held at University of Toronto

The 2013 Malignant Hyperthermia (MH) Scientific Conference is being held at the Chestnut Conference Centre, University of Toronto, Canada on November 1st and 2nd, 2013 and is sponsored by Malignant Hyperthermia Association of the United States (MHAUS) in conjunction with The University of Toronto.

29 Aug 2013

Malignant News and Research

New cellular switch could eventually inhibit growth of aggressive malignant brain tumor

Researchers discover new mechanism involving p53 to fight against aggressive cancers

Cardiovascular mortality in schizophrenia may be underestimated

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

Three-gene biomarker can help determine treatment option for early prostate cancer

T-rays are ideal for detecting early signs of melanoma

GGO-dominant lung tumors have excellent prognosis

Severity of sleep apnoea can independently predict aggressiveness of skin melanoma

Researchers investigate importance of STAT1 phosphorylation in NK cells

BMP linked to increased risk of benign tumors, not cancers

ESMO recognises oncologists with prestigious awards

Ontario researchers develop evidence-based recommendations for lung cancer screening

Researchers discover new way to target senescent cancer cells for destruction

Blind mole-rats live underground in low-oxygen environments, are long-lived and resistant to cancer

Researchers create specific tests to detect cancer biomarkers in patients with dermatomyositis

Anti-diabetic drug alogliptin meets primary endpoint in EXAMINE trial

Research findings could lead to new therapeutic approaches for liver cancer

Researchers receive $3M R01 award to test new approach to treating brain tumors

Researchers find new form of imaging technology to diagnose different types of cancer

Malignant Hyperthermia Scientific Conference to be held at University of Toronto

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News